State of Alaska Department of Revenue Lowers Stake in Moderna, Inc. $MRNA

State of Alaska Department of Revenue cut its position in Moderna, Inc. (NASDAQ:MRNA) by 3.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 38,124 shares of the company’s stock after selling 1,525 shares during the period. State of Alaska Department of Revenue’s holdings in Moderna were worth $1,051,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the company. S Bank Fund Management Ltd purchased a new stake in Moderna in the 1st quarter worth $25,000. TD Private Client Wealth LLC lifted its position in shares of Moderna by 348.8% in the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after acquiring an additional 743 shares in the last quarter. SVB Wealth LLC bought a new position in shares of Moderna in the first quarter worth about $28,000. CX Institutional grew its position in shares of Moderna by 1,129.8% during the second quarter. CX Institutional now owns 1,033 shares of the company’s stock worth $29,000 after purchasing an additional 949 shares in the last quarter. Finally, Costello Asset Management INC bought a new stake in Moderna during the 1st quarter valued at approximately $30,000. 75.33% of the stock is currently owned by institutional investors.

Moderna Price Performance

Shares of Moderna stock opened at $28.49 on Monday. The stock has a market cap of $11.08 billion, a price-to-earnings ratio of -3.78 and a beta of 2.01. The firm’s 50-day moving average is $26.30 and its two-hundred day moving average is $27.33. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $62.11.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating the consensus estimate of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business had revenue of $142.00 million during the quarter, compared to analyst estimates of $116.26 million. During the same quarter in the previous year, the business posted ($3.33) EPS. The company’s quarterly revenue was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. On average, equities analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Evercore ISI set a $32.00 price objective on shares of Moderna in a report on Friday, August 1st. Citigroup started coverage on shares of Moderna in a research report on Friday, August 1st. They set a “neutral” rating and a $40.00 target price for the company. Barclays reduced their price target on shares of Moderna from $40.00 to $31.00 and set an “equal weight” rating on the stock in a report on Monday, August 4th. Leerink Partners dropped their price objective on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating for the company in a report on Friday, August 22nd. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Moderna in a report on Sunday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, fourteen have issued a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat, Moderna currently has an average rating of “Hold” and an average target price of $41.81.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.